ArticleCureus2025
Primary Breast Lymphoma: A Rare Presentation of Diffuse Large B-Cell Lymphoma, Germinal Center B-Cell Subtype (DLBCL-GCB).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary breast lymphoma (PBL) is a rare type of extranodal lymphoma, accounting for only 0.5% of all breast malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of PBL, with the germinal center B-cell (GCB) subtype being an exceptionally rare clinical occurrence. This report describes a rare case of primary breast lymphoma of the DLBCL-GCB subtype, presenting as a rapidly enlarging breast mass. A 50-year-old female patient presented with a palpable, painless mass in her left breast. Despite a non-suspicious mammogram (breast imaging-reporting and data system (BI-RADS) 3), the presence of hypoechoic lesions with irregular margins in the ultrasound raised concern (BI-RADS IVc), prompting further imaging. Positron emission tomography-computed tomography (PET-CT) and MRI showed multifocal disease confined to the left breast and ipsilateral axillary lymph nodes, without distant metastasis. Core needle biopsy confirmed the DLBCL-GCB subtype. The patient was treated with eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. A mid-treatment PET-CT, performed after four cycles, demonstrated complete regression of hypermetabolic lesions in the left breast. The patient remains in remission on follow-up, suggesting a favorable early outcome. PBL poses diagnostic challenges due to its rarity and clinical overlap with more common breast malignancies. A thorough, multimodal diagnostic approach, combining imaging and histopathology, is essential to ensure accurate diagnosis. Management is primarily based on systemic chemotherapy, often complemented by radiotherapy, with treatment individualized according to disease extent and patient factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.